Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 106Pancreatic Neoplasms 31Esophageal Neoplasms 17Esophageal Squamous Cell Carcinoma 11Biliary Tract Neoplasms 11Colorectal Neoplasms 10Cholangiocarcinoma 6Neoplasm Metastasis 5Nasopharyngeal Carcinoma 5Adenocarcinoma 5Recurrence 4Head and Neck Neoplasms 4Gastrointestinal Neoplasms 4Colonic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Rectal Neoplasms 3Advanced Pancreatic Cancer 3Advanced Gastric Cancer 3Stage IV Gastric Cancer With Metastasis 2Neoplasms 2NSCLC 2Locally Advanced Gastric Cancer 2Gastric Cancer Peritoneal Metastases 2Gastric Adenocarcinoma 2Gallbladder Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2mCRC 1Surgically-Created Resection Cavity 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

camrelizumab 2apatinib 2trifluridine tipiracil drug combination 1tipiracil 1irinotecan sucrosofate 1Trifluridine 1S 1 (combination) 1Ramucirumab 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Metastatic Gastric Adenocarcinoma × S 1 (combination) × Clear all
NCT04781686 2021-05-17

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Zhongnan Hospital

Phase 2 Unknown
35 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡